The Shiga toxins Stx1 and Stx2 contribute to the development of enterohemorrhagic O157: H7 Escherichia coli-mediated colitis and hemolytic-uremic syndrome in humans. The Stx2 B subunit, which binds to globotriaosylceramide (GB3) receptors on target cells, was cloned. This involved replacing the Stx2 B subunit leader peptide nucleotide sequences with those from the Stx1 B subunit. The construct was expressed in the TOPP3 E. coli strain. The Stx2 B subunits from this strain assembled into a pentamer and bound to a GB3 receptor analogue. The cloned Stx2 B subunit was not cytotoxic to Vero cells or apoptogenic in Burkitt's lymphoma cells. Although their immune response to the Stx2 B subunit was variable, rabbits that developed Stx2 B subunit-specific antibodies, as determined by immunoblot and in vitro cytotoxicity neutralization assays, survived a challenge with Stx2 holotoxin. This is thought to be the first demonstration of the immunoprophylactic potential of the Stx2 B subunit.
toxin, the A-B subunits dissociate, and the A subunit's N-glycanase activity then removes adenine from position 4328 of the eukaryotic 28s rRNA [13] [14] [15] . The resulting A subunit-mediated inhibition of protein biosynthesis is cytotoxic to the target cell.
Many different STEC serotypes have been isolated from human cases of HC and HUS. In North America, O157:H7 remains the dominant serotype; in other regions of the world, serotypes such as O145:H Ϫ , O111:H Ϫ , and Out:H19 prevail [16, 17] . Regardless of serotype, Stx1 and Stx2 are uniformly expressed by virtually all human STEC. This universal expression of these toxins, in addition to their important role in the lifethreatening complications of STEC infections, makes these antigens attractive immunoprophylactic targets [18] .
In vitro assays indicate that Stx1 and Stx2 are serologically distinct, and antibodies to these toxins do not cross-neutralize their activities [1, 19, 20] . In contrast, in numerous studies of animals immunized with Stx1 or Stx2 toxoid preparations, the animals were cross-protected against a subsequent challenge by either toxin [21, 22] . However, this cross-protection was primarily due to the production of A subunit-specific antibodies. Other studies demonstrated that antibodies to the Stx1 or Stx2 B subunits are not cross-protective [21] [22] [23] .
Published evidence indicates a closer association between Stx2 expression by STEC and a more severe course of illness [24] [25] [26] . For example, in a recent outbreak involving 131 Japanese patients infected with an Stx1-producing O118:H2 STEC serotype, not one case of HUS was reported, and the gastrointestinal symptoms were relatively mild [24] . This contrasts with other STEC outbreaks involving serotypes that produced a combination of Stx1 and Stx2 or Stx2 alone: in those, the incidence of HUS was 5%-10% of infected subjects [27] [28] [29] . In a study of sporadic HUS cases, 94% involved STEC serotypes capable of producing Stx2 alone or a combination of Stx2 and Stx1; only 6% of cases developed HUS after infection with an STEC serotype that produced Stx1 only [30] . Finally, Stx2 is more lethal than Stx1 in mice [31] and causes a greater gastrointestinal pathology in rabbits [32] .
The immunoprophylactic potential of the Stx1 B subunit has been thoroughly documented in the literature [33] [34] [35] . However, given the importance of Stx2 in STEC disease and that antiStx1 B subunit antibodies do not confer protection against an Stx2 holotoxin challenge, any potential STEC vaccine must generate a protective Stx2 immune response. Although animals immunized with Stx2 toxoid preparations are protected against a holotoxin challenge [22] , there are safety concerns associated with using inactivated holotoxins in human vaccines, especially when the incidence of the disease is low. Therefore, if a practical Stx-based acellular STEC vaccine is to be developed, the atoxic Stx2 B subunit would be a potential component.
Unlike the cloning and expression of the Stx1 B subunit [36] [37] [38] , cloning and expression of the Stx2 B subunit has been more challenging [39] . It has been suggested that this might be due to the instability of the multimeric Stx2 B subunit in E. coli expression systems [39] . We therefore speculated that the difference between the expression of the Stx1 B and Stx2 B subunits might be in the processing steps involved in their secretion into the periplasmic space in E. coli. Following this reasoning, we discovered that interchanging the Stx1 and Stx2 B leader peptide nucleotide coding sequences solved the Stx2 B cloning problem. We subsequently determined the physical, biologic, and immunologic properties of the recombinant Stx2 B subunit.
Materials and Methods
Plasmid construction. Standard techniques were used to construct the plasmids [40] . All restriction enzymes were obtained from Gibco BRL Life Technologies. Plasmids were isolated from the bacteria by the mini DNA preparation procedure described by Elango et al. [41] . All constructs were characterized by polymerase chain reaction (PCR), were restriction digested, and were sequenced with a Sequenase kit (version 2; United States Biochemicals).
The stx1b leader sequence was amplified by PCR from pVERO (obtained from B. Ritchie, Dept. of Biochemistry, University of Alberta, Edmonton, Canada) by using primers 1 (5 -GAA GGA GAT ATG CAT ATG AAA A-3 ) and 2 (5 -ATC AGC TGC AGC CAG CGC ACT TGC TGA-3 ). The resulting 60-bp fragment and pRSETB vector (Invitrogen) were digested with NdeI and PstI (sites introduced by primers) and were ligated. Electrocompetent DH5a E. coli cells (Bethesda Research Laboratories) were transformed, and the resulting isolated plasmid was designated pSTX1BLS.
The stx2b gene, minus the leader peptide coding sequences, was amplified by PCR from chromosomal DNA isolated from E. coli C600 containing the 933W bacteriophage [42] (gift of D. Acheson, Dept. of Geographic Medicine, New England Medical Center, Boston, Massachusetts). Primer 3 (upstream; 5 -AAT GGC TGC AGA TTG CGC TAA AGG TAA-3 ) and primer 4 (downstream; 5 -CAG GTG GTA CCT CAG TCA TTA TTA AAC-3 ) introduced restriction enzyme sites PstI and KpnI, respectively. The 220-bp fragment and pSTX1BLS were digested with PstI and KpnI and were ligated. Electrocompetent DH5a E. coli were transformed; the isolated plasmid was designated pSTX2BSTX1BLS.
The stx2b gene, including its native leader peptide coding sequences, was amplified by PCR from chromosomal DNA isolated from E. coli C600 containing the bacteriophage 933W by using primers 5 (5 -GAG ATA TAC ATA TGA AGA AGA TGT TTA TGG C-3 ) and 4 (same as above). The 280-bp fragment and pRSETB were digested with restriction enzymes NdeI and KpnI. Electrocompetent DH5a E. coli were transformed, and the isolated plasmid was named pSTX2B.
Stx2 B expression. pSTX2BSTX1BLS, pSTX2B, and pRSETB were transformed into E. coli strain TOPP3 (rif r [F , proAB, lacI q ZÄ M15,Tn10(tet r )] km r ; Stratagene). Isolated colonies were then grown with shaking at 225 rpm (G10 Gyrotory Shaker; New Brunswick) at 30ЊC to midexponential phase (A600, 0.6) in 5 mL of Luria-Bertani (LB) broth (Difco Laboratories) supplemented with 50 mg/mL ampicillin (Sigma Aldrich). The cultures were subsequently heat-induced by doubling their volume with fresh LB preheated to 55ЊC. These cultures were then incubated at 42ЊC for an additional 30 min and were grown another 4 h at 37ЊC with shaking at 225 rpm (G10 Gyrotory Shaker). We collected 75-mL aliquots of these bacterial cultures by centrifugation. The resulting cell pellets were lysed in 25 mL of Laemmli sample buffer [43] and were analyzed by SDS-PAGE with the Mini-PROTEAN II cell system (Bio-Rad). Protein bands from the resulting SDS gel were electrophoretically transferred for 15 min at 0.5 A with a TransBlot cell (Bio-Rad) to a polyvinylidene difluoride (PVDF) membrane (Millipore). The Western blot was subsequently cut in half, and the top half of the blot was probed with a 1:10,000 dilution of polyclonal rabbit antimaltose binding protein (New England Biolabs). The bottom half was probed with a 1:1000 dilution of polyclonal rabbit Stx2 B subunit-specific antiserum raised from native B subunits purified from the holotoxin. This was followed with a 1:10,000 dilution of the secondary antibody, peroxidaseconjugated goat anti-rabbit IgG (Sigma Aldrich) and was developed with the ECL Western blotting detection kit (Amersham Pharmacia Biotech), according to the manufacturer's instructions. The blot was exposed for 2 min to x-ray film (Super RX; Fuji Photo).
Large scale isolation and purification of recombinant Stx2 B subunit. The E. coli TOPP3 pSTX2BSTX1BLS clone was grown to midexponential phase (A600, 0.6) at 30ЊC with shaking at 225 rpm (G10 Gyrotory Shaker) in 500 mL of ampicillin-supplemented (50 mg/mL) LB. These cultures then were heat induced for Stx2 B subunit expression, as described above. The Stx2 B subunit was purified by using 15 g of Synsorb-Pk (Synsorb Biotech) [44] , as described by Mulvey et al. [18] , with these minor modifications. The Stx2 B subunit was eluted from the Synsorb-Pk in mL 2 ϫ 100 of 1 M urea, 0.25 M NaCl, and 0.05 M Tris (pH 10.0), with shaking at 150 rpm at 37ЊC for 30 min. The eluted fractions then were filter sterilized through 0.22-mm pore size filter units (Steritop; Millipore) and were concentrated 75 times by using a stirred-cell filtration apparatus (Amicon) fitted with a YM-3 membrane (Millipore). Urea was removed from these samples by diluting them to their original volume with 0.05 M Tris and 0.25 M NaCl buffer (pH 10), less the urea, and the concentration step was repeated. This filtration dialysis procedure was done 3 times in all. Protein yield was determined by BCA Protein Assay Kit (Pierce), according to the manufacturer's instructions. Stx2 holotoxin preparation. Stx2 holotoxin was purified from E. coli C600 933W [42] . Affinity purification of Stx2 was accomplished by using Synsorb-Pk [44] , according to the published procedure [18] , with the minor modifications detailed above.
Vero cytotoxicity assays of purified recombinant Stx2 B subunit and Stx2 holotoxin. Purified Stx2 holotoxin and the Stx2 B subunit were assayed for toxicity in Vero cells by following a procedure described elsewhere [18, 45] .
High-performance liquid chromatography (HPLC) gel filtration of recombinant Stx2 B subunit. We injected ∼150 mg of purified Stx2 B subunit at a flow rate of 0.4 mL/min into an SE-100117 BioPrep HPLC column (Bio-Rad) equilibrated with 0.15 M NaCl and 0.05 M Na/K buffer (pH 6.8). The column was calibrated with standard proteins (Bio-Rad). The elution profile was recorded at a wavelength of 280 nm.
Binding ELISA with recombinant Stx2 B subunit. ELISAs were done in triplicate. In total, 100 mL/well of a bovine serum albumin (BSA) glycoconjugate containing an average of 24 M of 8 methoxycarbonyloctyl (MCO) Pk trisaccharide (aGal [1, 4] bGal [1, 4] bGlc) sequences/mol was coated overnight at 4ЊC in 96-well EIA/RIA microtiter plates (Costar). The MCO Pk trisaccharide-BSA was a gift of D. Bundle (Dept. of Chemistry, University of Alberta, Edmonton). Control wells were coated with unconjugated BSA. The plates were washed 5 times with PBS buffer (pH 7.3) containing 0.05% Tween (PBST) and were blocked for 1 h at room temperature with 200 mL/ well of 2% BSA (Sigma Aldrich) in PBST. The plates were washed 5 times with PBST buffer, and 100 mL/well of 1:5 serial dilutions of Stx2 B subunit (or Stx2 holotoxin), starting at 10 mg/mL, was added overnight at room temperature. The plates then were washed 5 times with PBST, and 100 mL/well of a 1:100 dilution of polyclonal rabbit Stx2 B subunit antiserum was added for 1 h at room temperature. The plates were washed 5 times with PBST, and a 1:5000 dilution of peroxidase-conjugated goat anti-rabbit IgG was added for 1 h at room temperature. The plate was finally washed 5 times with PBST and was developed for 30 min at room temperature with 200 mL/ well of 10 mM Citrate buffer (pH 4.2), 0.06% H 2 O 2 , and 0.055% 2,2 -azino-di-[3-ethylbenzthiazoline sulfonate] (ABTS; Boehringer Mannheim). The resulting absorbance data were recorded with a Spectramax 340 microtiter plate reader (Molecular Devices) set at a wavelength of 405 nm.
Apoptosis assays with Stx2 B subunit and Stx2 holotoxin. The GB3-expressing Burkitt's lymphoma cell line, Daudi, was purchased from American Type Culture Collection (catalog no. CCL-213). The cells were cultivated in RPMI 1640 medium (Gibco BRL) supplemented with 1 mM glutamine and 10% heat-inactivated fetal bovine serum (FBS). We cultivated the Burkitt's lymphoma cells ( cells/mL) for 18 h in the presence of either 5 mM Camp- 6 4.6 ϫ 10 tothecin (Sigma Aldrich), 10 ng/mL Stx2, or 1 mg/mL Stx2 B. Apoptotic cells were labeled as described in the in situ cell death detection kit (Boehringer Mannheim) and then were quantified by flow cytometry (fluorescence at 525 nm) with a FACscan flow cytometer (Becton Dickinson). Endotoxin quantification and removal from cloned Stx2 B subunit. We determined the endotoxin concentration in the Stx2 B subunit preparations with a colorimetric Limulus amebocyte lysate assay kit (QCL-1000; BioWhittaker) and recorded results as endotoxin units per milliliter of protein solution. Excess endotoxin was removed from the purified Stx2 B subunit preparations with Detoxi-Gel (Pierce), according to the manufacturer's directions. The endotoxin content of 10 mg of Stx2 B subunit was reduced to 0.4 endotoxin U/mL (low endotoxin) by passing 0.2 mL of the sample 4 times through a 1-mL (bed volume) Detoxi-Gel column (Pierce). The protein recovery was ∼80%-90% at each passage through the column.
Rabbit immunization procedures. We used 8 female New Zealand White rabbits (Vandermeer Rabbitry), weighing ∼2 kg each, in 2 groups of 4. The rabbits in 1 group were injected in the subscapular region with the cloned low endotoxin Stx2 B subunit preparation homogenized in an equal volume of Quil-A Saponin (Cedarlane Laboratories) adjuvant. The rabbits in the second group were sham immunized with a 1:1 homogenate of Quil-A and pyrogen-free 0.9% NaCl irrigation solution (United States Pharmacopoeia; Baxter). The rabbits were injected 3 times, on a monthly schedule, the first time with 150 mg of antigen and each subsequent time with 100 mg of antigen.
The 8 rabbits then were subgrouped for a second round of immunization. Four rabbits, 2 from the low endotoxin Stx2 B subunit-immunized group and 2 from the sham-immunized control group, were given 2 additional 100-mg injections of a cloned Stx2 B subunit preparation, in which the endotoxin concentration had only been reduced to 2000 endotoxin U/mL (high endotoxin Stx2 B subunit preparation). The remaining 4 rabbits, 2 previously immunized with the low endotoxin Stx2 B subunit preparation and 2 from the sham-immunized control group, received 2 additional 100-mg injections of the low endotoxin Stx2 B subunit preparation. Table 1 summarizes the immunization schedule for each rabbit.
Analysis of rabbit serum samples by Western immunoblot. Serum samples were drawn from the ear vein of each rabbit. Preand postimmunization serum samples then were analyzed for specific antibody production by Western immunoblot. SDS-PAGE of Stx2 holotoxin was performed, and proteins from the resulting SDS gels were electrophoretically transferred to PVDF membranes. The immunoblots then were probed with a 1:5000 dilution of each rabbit serum sample followed by a 1:10,000 dilution of peroxidase- conjugated goat anti-rabbit IgG. The immunoreactive protein bands were detected by ECL Western immunoblot detection kit with a 1-min exposure to Super RX Fuji medical x-ray film.
Analysis of rabbit serum samples by Vero cytotoxicity neutralization assay. Rabbit serum samples were serially diluted in duplicate in PBS (pH 7.3) in 96-well microtiter plates. We mixed 5 mL of 2 mg/mL Stx2 holotoxin in PBS with 75 mL of each of the serial dilutions. After 1 h of incubation at 37ЊC, 20 mL from each well in the dilution plates was transferred to the corresponding well of a 96-well plate containing confluent Vero cell monolayers and 200 mL of MEM supplemented with 5% FBS (Gibco BRL Life Technologies). After 2 h, the MEM was emptied from the Vero cell microtiter plates. After each monolayer was washed twice with 200 mL/well MEM, fresh MEM plus 5% FBS was added to the wells, and the plates were incubated an additional 46 h at 37ЊC in 5% CO 2 /95% air. The Vero cells then were fixed with methanol and Giemsa stained (Fisher). The results were recorded with a Spectramax 340 microtiter plate reader set at a wavelength of 620 nm, and data were analyzed as described elsewhere [45] .
ELISA determination of antibody titers. We determined IgG titers in the rabbit serum samples in triplicate by ELISA. We coated 200 mL/well of 2.5 mg/mL Stx2 overnight at 4ЊC in 96-well EIA/ RIA plates. The plates then were washed 5 times with PBST and were blocked with 2% BSA, as described earlier. In total, 200 mL of serial dilutions of serum samples in 2% BSA and PBST was added to the wells, and the plates were incubated for 2 h. The plates then were washed 5 times with PBST, and 200 mL/well of a 1:5000 dilution of peroxidase-conjugated goat anti-rabbit IgG was added for 1 h at room temperature. The plates were washed 5 times with PBST and were developed with ABTS, and the results were recorded at 405 nm, as described earlier.
Rabbit Stx2 holotoxin challenge experiments. Rabbits were challenged with 5 mg of Stx2 holotoxin per kilogram of body weight [46] . The purified Stx2 holotoxin preparations were homogenized with an equal volume of Quil-A adjuvant and were injected into the subscapular region of each rabbit. The rabbits then were monitored every 4 h for 1 week and thereafter once daily for 3 weeks. The rabbits were killed as soon as toxic effects (anterior ataxia or paralysis) were observed. At the end of the 1-month study, asymptomatic surviving rabbits were also killed for postmortem examination.
Postmortem and micropathology studies were done on the brain, liver, spleen, kidneys, jejunum, cecum, and colon of each rabbit. These organs were removed and were placed in 10% neutral buffered formalin for fixation. After 24-48 h in the fixative solution, samples were trimmed into tissue cassettes, were processed into paraffin blocks, were thin sectioned, were stained with hematoxylin-eosin, and were mounted on glass microscope slides by standard techniques. A board-certified veterinary pathologist examined the sections.
Results

Expression of recombinant Stx2 B subunit.
Western immunoblotting analysis of whole cell lysates of the TOPP3 E. coli clones containing the plasmid constructs pSTX2BSTX1BLS or pSTX2B revealed that only the clone containing pSTX2B-STX1BLS (stx2b with the stx1b leader sequence) expressed an immunoreactive protein that comigrated with the Stx2 B subunit band in the positive control lane ( figure 1, bottom, lane 2) containing Stx2 holotoxin. E. coli isolates containing the empty expression vector pRSETB or the vector containing the native Stx2 B subunit insert (pSTX2B, stx2b with its native leader sequence) failed to express detectable levels of the Stx2 B subunit. The immunoblot in figure 1 also demonstrated that the E. coli TOPP3 pSTX2BSTX1BLS strain only expressed detectable levels of Stx2 B subunit after heat induction. The Western immunoblot in figure 1 (top) was probed with antibodies to constitutively expressed maltose-binding protein. These results showed that equal amounts of extracts from each of the E. coli strains analyzed by this procedure were applied to the SDS-PAGE lanes.
Purification of the Stx2 B subunit. Expression and purification of the Stx2 B subunit were done by using TOPP3 pSTX2BSTX1BLS E. coli. The average yield of purified Stx2 B protein from 12 independent 4-L preparations was 0.7 mg/ L (range, 0.3-1 mg/L). This yield compared favorably with the 0.1 mg/L yield obtained in the procedure described by Acheson et al. [39] . SDS-PAGE analysis of the purified Stx2 B subunit is shown in figure 2 . Densitometry analysis of the protein bands on the SDS polyacrylamide gels revealed 195% purity in the Synsorb-Pk-purified Stx2 B preparations.
Vero cytotoxicity assay of Stx2 B subunit and Stx2 holotoxin. Recombinant Stx1 B subunit is nontoxic [37, 38] and does not induce apoptosis in Vero cells [47] . Thus, we studied the Vero cytotoxicity of our recombinant Stx2 B subunit preparations and purified Stx2 holotoxin. The 50% cell death (CD 50 ) of purified Stx2 holotoxin in Vero cells was 38 pg/mL, which is consistent with previous Stx2 CD 50 values in Vero cells [18, 48] . The recombinant Stx2 B subunit was nontoxic in the Vero cytotoxicity assay at р5 mg/mL (data not shown). These results are consistent with prior published results for the cloned Stx1 B subunit [37, 38] .
Molecular mass estimation of Stx2 holotoxin and Stx2 B subunit. The molecular mass of the recombinant Stx2 B subunit was determined by HPLC gel filtration chromatography (data not shown). The Stx2 B subunit eluted from the calibrated HPLC column as one sharp symmetrical peak with a calculated mass of 38 kDa. This value closely approximates the theoretical mass (39,085 Da) of the Stx2 B pentamer.
Stx2 B subunit binding to MCO Pk-BSA. The ELISA data shown in figure 3 revealed that the cloned Stx2 B subunit bound to a receptor analogue in a similar manner to that of Stx2 holotoxin.
Apoptosis assay results with Burkitt's lymphoma cells. We used the in situ terminal deoxynucleotide transferase-mediated dUTP nick end labeling procedure to determine whether the cloned Stx2 B subunit induced apoptosis in GB3-expressing Daudi Burkitt's lymphoma cells. Stx2 holotoxin was also tested for comparison. Camptothecin, an apoptogenic agent, induced apoptosis at 5 mM in 28% of cells. Stx2 induced apoptosis in 20% of the Daudi cells at 10 ng/mL, which is similar to other apoptosis results for Stx1 holotoxin [49] ; however, unlike the Stx1 B subunit [49] , the Stx2 B subunit did not induce apoptosis at р100-fold concentration (1 mg/mL; results not shown).
Low endotoxin Stx2 B subunit as an immunogen in rabbits. The endotoxin concentration (110 6 U/mL) in the Synsorb-Pkpurified Stx2 B subunit preparations was considered to be unacceptable for vaccine preparations. Therefore, we used polymyxin-B-agarose (Detoxi-Gel) affinity chromatography, to reduce the endotoxin concentration to !0.4 U/mL in these antigen preparations. Although 4 rabbits were immunized 3 times for 3 months with the low endotoxin Stx2 B preparation, Western immunoblot analysis revealed no evidence of Stx2 B subunitreactive antibodies in serum samples obtained from these animals (results not shown). In addition, none of the serum samples from these low endotoxin Stx2 B subunit-immunized animals, even at the lowest dilution tested (1:20) , protected Vero cells from a cytolethal dose of Stx2 holotoxin (data not shown). However, ELISA data indicated that, despite the negative Western immunoblot and Vero cytoxicity neutralization assay results, some anti-Stx2 antibodies were being produced in the immunized animals. As anticipated, none of the preimmunization serum samples from the 8 rabbits nor any serum samples from the 4 sham-immunized control animals contained evidence of Stx2-reactive antibodies by ELISA, immunoblot, or Vero cytotoxicity neutralizing assays (results not shown).
Immunization with a high endotoxin Stx2 B subunit preparation. Endotoxin is an immunogen and has adjuvant properties [50, 51] . We therefore thought the presence of some endotoxin might augment the rabbit immune response to the Stx2 B subunit. To test this theory, 2 of the rabbits previously immunized (primed) with the low endotoxin Stx2 B preparation were injected 2 more times with a partially detoxified (high endotoxin) Stx2 B subunit preparation containing ∼2000 endotoxin U/mL (table 1) . The other 2 rabbits from this group were injected 2 more times with the same low endotoxin Stx2 B preparation they received in the first round of immunization. The 4 control rabbits from the first round of immunization were injected 2 more times with either the low (2 rabbits) or high endotoxin (2 rabbits) Stx2 B subunit preparations (table 1) .
Western immunoblot analysis of serum samples after this Fate of rabbits challenged with lethal dose of Stx2 holotoxin. Rabbits were killed when obvious signs of Stx2 holotoxin-mediated symptoms (anterior ataxia or diarrhea) became apparent. Rabbits K103, K106, and K110 remained healthy and were killed for micropathologic examination at end of 1-month study.
second round of immunizations revealed that rabbits K106 and K110, which were primed with 3 injections of the low endotoxin Stx2 B subunit preparation and then were injected twice with high endotoxin (∼2000 U/mL) Stx2 B subunit, developed a specific antibody response to the immunogen after the first of the 2 additional injections ( figure 4A ). In addition, after receiving 2 injections of the low endotoxin Stx2 B preparation, 1 of the first round, sham-immunized control rabbits, K103, produced a specific antibody response to the Stx2 B subunit ( figure 4B ). Rabbit K107, another of the first round shamimmunized animals, produced a weak antibody response (figure 4) to the Stx2 B subunit after 2 injections with the high endotoxin Stx2 B subunit preparation. Vero cytotoxicity neutralization assays demonstrated that the second round hyperimmune serum samples from rabbits K106 and K110 protected Vero cells from a lethal dose of Stx2 holotoxin at р1:160 and 1:40 dilutions, respectively (results not shown). However, despite Western immunoblot evidence of Stx2 B subunit-specific reactivity in the postimmunization serum samples from rabbits K103 and K107, these serum samples were not neutralizing in the Vero cytotoxicity assay. Also, the ELISA antibody titers of the serum samples from all the immunized rabbits (table 1) did not correlate either with the endotoxin content of the Stx2 B subunit preparations or with Western immunoblot or Vero cytotoxicity protection results.
Rabbit challenge with Stx2 holotoxin. All the Stx2 holotoxin-challenged rabbits that failed to display Western immunoblot evidence of Stx2 B subunit-specific antibodies developed Stx2-related symptoms between postchallenge days 2 and 4 and were killed (figure 5). Rabbit K107, which developed a weak Western immunoblot response to the Stx2 B subunit, also developed Stx2-related symptoms on postchallenge day 2 and was killed. In contrast, rabbits K103, K106, and K110, which produced Western immunoblot-positive Stx2 B subunit antibodies, remained asymptomatic throughout the 1-month study. At postmortem examination, all the unprotected rabbits displayed various degrees of Stx-mediated organ and tissue damage. In contrast, all tissues and organs in each of the protected rabbits (K103, K106, and K110) appeared to be normal (data not shown).
The Stx2 B subunit band was not the only immunoreactive band visible in the Western immunoblots shown in figure 4 . The patterns of these non-Stx2 B subunit immunoreactive bands also varied between serum samples from the different rabbits and were less intense than the Stx2 B subunit-immunoreactive band. These non-Stx2 B subunit-immunoreactive bands could have resulted from antibodies specific to minor impurities in the immunogen preparations. Alternatively, the Stx2 B subunit-specific antibodies may have recognized SDS-resistant polymerized forms of the Stx2 B subunit on the Western immunoblots. The only common immunoreactive band in the Western immunoblots prepared with serum samples from all the protected rabbits (K103, K106, and K110) was the Stx2 B subunit band.
Discussion
By substituting the native peptide leader sequence of the Stx2 B subunit with that of the Stx1 B subunit, we obtained highly purified, apparently pentameric, native Stx2 B subunits in the TOPP3 E. coli expression strain. The cloned Stx2 B subunit was purified to near homogeneity (195% purity) by affinity batch purification by using Synsorb-Pk, a compound consisting of an insoluble matrix that contains covalently linked Stx2 trisaccharide receptor analogues [18, 44] (figure 2). This implied that the Stx2 B subunits retained their ability to bind to receptors. This activity was confirmed by the ELISA results shown in figure 3 .
Because the recombinant Stx2 B subunit might be used in a potential acellular EHEC vaccine, any evidence of biologic activity in this recombinant Stx2 B subunit would be of concern. Elsewhere it was reported that a recombinant Stx1 B subunit preparation induced apoptosis in Burkitt's lymphoma [49] and astrocytoma cells [52] . However, there are conflicting views on the apoptotic activity of the Stx1 B subunit. Nakagawa et al. [53] recently showed that HeLa cells transfected with the stx1b gene undergo apoptosis. In contrast, Calderwood et al. [36] reported that recombinant Stx1 B subunit is nontoxic to HeLa cells at р10 mg/mL. Williams et al. [47] showed that the Stx1 B subunit does not induce apoptosis in Vero cells. More recent studies showed that the Stx A subunit, not the B subunits, is essential for activating cellular proteins thought to be involved in the apoptosis signaling cascade [54, 55] . We therefore tested the apoptotic activity of our cloned Stx2 B subunit and found that it did not induce apoptosis in Burkitt's lymphoma cells.
Stx2 holotoxin, in comparison with Stx1 holotoxin, has a lower affinity for its receptor [56] . Structural studies of the Stx1 B pentamer also showed that each monomer protein contains 3 possible functional carbohydrate receptor binding sites [57] . In contrast, studies on a mutant Stx2e B subunit showed that the third site in this variant Stx may not be functional in binding GB3 [58] . Experiments with chimeric proteins made with Stx1 A subunit and Stx2 B subunit (and vice versa) revealed that the different cytotoxic effects of the 2 toxins are specific to their B subunits [56] . Therefore, there are many possible explanations for why our cloned Stx2 B subunit, unlike the Stx1 B subunit, failed to induce apoptosis in Burkitt's lymphoma cells.
In the first round of immunization, the lack of an apparent immune response to the Stx2 B subunit might have been due to insufficient augmentation of the rabbit immune system by the Quil-A adjuvant. Endotoxin (lipopolysaccharide [LPS]) has adjuvant properties and stimulates both humoral and cell-mediated immunity [50, 51] . Therefore, the hyporeactivity of the rabbit immune system to the low endotoxin Stx2 B subunit may have been due to the lack of adjuvant activity in this antigen preparation. Our finding that endotoxin may have stimulated an immune response to the cloned Stx2 B subunit is consistent with this hypothesis. It is also possible that endotoxin in the antigen preparations may have sufficiently primed the rabbit immune system so that the challenge antigen, Stx2 holotoxin, could rapidly generate a protective immune response, perhaps directed at the immunodominant A subunit. We believe, however, that the results in rabbit K103, which survived the Stx2 holotoxin challenge after receiving only the low endotoxin Stx2 B subunit preparation, run counter to this alternative explanation for the role of endotoxin in this system.
Western immunoblotting and Vero cytotoxicity neutralization assays revealed that rabbits K106 and K110 developed Stx2 B subunit-specific antibodies after receiving additional injections of high endotoxin Stx2 B subunit. Western immunoblot analysis also revealed a Stx2 B subunit-specific antibody response in rabbit K103, which received only 2 injections of the low endotoxin Stx2 B subunit. However, the serum samples from this animal did not neutralize Stx2 holotoxin cytotoxicity in Vero cells. This result underscores the potential for population-level differences in the quality of an immune response to immunogens such as the low endotoxin Stx2 B subunit preparation. Such differences may also be apparent in the lack of correlation between the ELISA results and variable patterns of Western immunoblot-reactive bands in serum samples from animals receiving identical immunogen preparations ( figure 1 and  table 1 ).
The data in figure 4A indicate that rabbits K106 and K110, which were primed by 3 injections of the low endotoxin Stx2 B subunit, produced an anti-Stx2 B subunit immune response after only 1 injection of the high endotoxin Stx2 B subunit preparation. Unlike these primed rabbits, the 2 animals that received only 2 injections of high endotoxin Stx2 B subunit (K107 and K111) did not develop (K111) or developed only a weak (K107) antibody response to the Stx2 B subunit. This suggests that simply including endotoxin in the Stx2 B subunit preparation was not sufficient to induce a protective immune response after only 2 injections of immunogen.
Acheson et al. [39] evaluated several Stx2 B subunit cloning and expression strategies. These included expressing the Stx2 B subunit behind the T7 or tac promoters in E. coli and Vibrio cholerae and constructing an Stx2 B subunit-maltose binding protein fusion. Although, they produced anti-Stx2 B subunit antibodies in rabbits, the antisera were not protective in tissue culture cell neutralization assays nor did they proceed to test the immunoprophylactic activity of their cloned antigens in vivo. They attributed the lack of cytotoxicity neutralization to pentamer stability problems. It is possible that, had this group [39] challenged their immunized rabbits with Stx2 holotoxin, they may have survived, akin to our rabbit K103, whose postimmune serum was Stx2 B subunit immunoblot positive and Vero cytotoxicity neutralization negative. Although high concentrations of endotoxin are unacceptable in vaccines, alternatives could be included with the Stx2 B subunit. With the advent of new generation multicomponent vaccines, including recombinant subunit and synthetic peptide vaccines, eliciting a protective immune response to these purified antigens has proven challenging, and the search for safe adjuvants has become an essential part of this enterprise [59] . Human trials are now underway to increase the number of approved adjuvants and to overcome the difficulties involved with the immunoreactivity of some of the new generation vaccine formulations. These experimental adjuvants include, among others, the detoxified LPS molecule, monophosphoryl lipid A [60, 61] , and a saponin derivative, QS21 [62, 63] . Ongoing work in our laboratory is directed at determining which of the new generation adjuvants may be used most effectively to enhance the protective properties of the cloned Stx2 B subunit in future potential STEC vaccines. Nonetheless, with this present study, we demonstrated that it is possible to generate an active Stx2 B subunit-specific protective immune response in animals. Our results elaborate on the work by Nakao et al. [64] , who previously reported on the immunotherapeutic potential of Stx2 B subunit-specific antibodies.
